Octapharma Pharmazeutika Produktionsges.m.b.H.

Octapharma, a Swiss-based company, is an independent, global plasma fractionation specialist. Its core business is the development, production and sale of high quality plasma derivatives.

The company has grown to 3,000 employees in 28 countries since its founding in 1983. Octapharma owns five modern, state-of-the-art production facilities in Austria, France, Germany, Sweden and Mexico. Sales turnover in 2008 reached Euro 886 million. Since the foundation of Octapharma in 1983, the company has established a clear and consistent mission: for the safe and optimal use of plasma. This mission statement has stood the test of time and has driven our activities in the last 26 years.

Over the past six years, in addition to our plasma-based activities, Octapharma has dedicated increasing resources to recombinant product research and development based on the use of human cell lines. Our recombinant R&D department in Sweden has completed pre-clinical toxicology testing in animals and clinical trials in humans will start in 2009.

This unique approach sets us apart from other companies whose recombinant products are based on animal (murine) cells. Octapharma respects donated human plasma as a scarce and valuable resource. By using leading edge, validated viral inactivation and purification technologies Octapharma aims to achieve the highest production yields and produce products with the highest possible safety margins.

This unique approach sets us apart from other companies whose recombinant products are based on animal (murine) cells.